Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis

Results of a multicenter randomized controlled trial

Dana S. Hardin, Beverley Adams-Huet, Daniel Brown, Barbara Chatfield, Maynard Dyson, Thomas Ferkol, Michelle Howenstine, Claude Prestidge, Frederick Royce, Julie Rice, Dan K. Seilheimer, Joel Steelman, Ross Shepherds

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Context: This multicenter, randomized, controlled, crossover trial of prepubertal children with cystic fibrosis (CF) tests the hypotheses that recombinant human GH (rhGH) treatment 1) improves height, weight, lean mass, and bone content irrespective of baseline measures; 2) improves clinical status and quality of life; and 3) has continued effect after cessation after 1 yr of treatment. Methods: Sixty-one prepubertal subjects (≤25th percentile for height and weight) were randomized into two groups: daily rhGH treatment or no treatment groups for 1 yr. In yr 2, treatments were crossed over. Outcome measures included serial standardized height and weight, number of hospitalizations and antibiotic courses, random blood glucose levels, lean mass, bone mineral content, pulmonary function, nutritional intake, and CF quality of life questionnaires. Results: Groups were similar at baseline and prepubertal during the entire study. After 1 yr, GH showed significantly greater gain in height, weight, lean mass, and bone mineral content. Gain in height was similar regardless of baseline. There were fewer hospitalizations in the rhGH-treated group and improvement in CF quality of life questionnaires measures of weight and body image. There was no difference in pulmonary function between groups. Results were similar in those treated with rhGH the second year. After cessation of rhGH treatment, there was sustained effect for increased height and weight velocity, as well as accrual of bone mineral. Conclusion: rhGH therapy improves height and weight, decreases the number of hospitalizations, and improves quality of life in prepubertal children with CF. These effects are sustained after rhGH is discontinued.

Original languageEnglish
Pages (from-to)4925-4929
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number12
DOIs
StatePublished - Dec 2006

Fingerprint

Cystic Fibrosis
Growth Hormone
Bone
Randomized Controlled Trials
Minerals
Weights and Measures
Growth
Quality of Life
Hospitalization
Bone Density
Therapeutics
Blood Glucose
Bone and Bones
Lung
Anti-Bacterial Agents
Body Image
Cross-Over Studies
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis : Results of a multicenter randomized controlled trial. / Hardin, Dana S.; Adams-Huet, Beverley; Brown, Daniel; Chatfield, Barbara; Dyson, Maynard; Ferkol, Thomas; Howenstine, Michelle; Prestidge, Claude; Royce, Frederick; Rice, Julie; Seilheimer, Dan K.; Steelman, Joel; Shepherds, Ross.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 91, No. 12, 12.2006, p. 4925-4929.

Research output: Contribution to journalArticle

Hardin, DS, Adams-Huet, B, Brown, D, Chatfield, B, Dyson, M, Ferkol, T, Howenstine, M, Prestidge, C, Royce, F, Rice, J, Seilheimer, DK, Steelman, J & Shepherds, R 2006, 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: Results of a multicenter randomized controlled trial', Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 12, pp. 4925-4929. https://doi.org/10.1210/jc.2006-1101
Hardin, Dana S. ; Adams-Huet, Beverley ; Brown, Daniel ; Chatfield, Barbara ; Dyson, Maynard ; Ferkol, Thomas ; Howenstine, Michelle ; Prestidge, Claude ; Royce, Frederick ; Rice, Julie ; Seilheimer, Dan K. ; Steelman, Joel ; Shepherds, Ross. / Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis : Results of a multicenter randomized controlled trial. In: Journal of Clinical Endocrinology and Metabolism. 2006 ; Vol. 91, No. 12. pp. 4925-4929.
@article{582c600c742b49198e8b7743e3050bf2,
title = "Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: Results of a multicenter randomized controlled trial",
abstract = "Context: This multicenter, randomized, controlled, crossover trial of prepubertal children with cystic fibrosis (CF) tests the hypotheses that recombinant human GH (rhGH) treatment 1) improves height, weight, lean mass, and bone content irrespective of baseline measures; 2) improves clinical status and quality of life; and 3) has continued effect after cessation after 1 yr of treatment. Methods: Sixty-one prepubertal subjects (≤25th percentile for height and weight) were randomized into two groups: daily rhGH treatment or no treatment groups for 1 yr. In yr 2, treatments were crossed over. Outcome measures included serial standardized height and weight, number of hospitalizations and antibiotic courses, random blood glucose levels, lean mass, bone mineral content, pulmonary function, nutritional intake, and CF quality of life questionnaires. Results: Groups were similar at baseline and prepubertal during the entire study. After 1 yr, GH showed significantly greater gain in height, weight, lean mass, and bone mineral content. Gain in height was similar regardless of baseline. There were fewer hospitalizations in the rhGH-treated group and improvement in CF quality of life questionnaires measures of weight and body image. There was no difference in pulmonary function between groups. Results were similar in those treated with rhGH the second year. After cessation of rhGH treatment, there was sustained effect for increased height and weight velocity, as well as accrual of bone mineral. Conclusion: rhGH therapy improves height and weight, decreases the number of hospitalizations, and improves quality of life in prepubertal children with CF. These effects are sustained after rhGH is discontinued.",
author = "Hardin, {Dana S.} and Beverley Adams-Huet and Daniel Brown and Barbara Chatfield and Maynard Dyson and Thomas Ferkol and Michelle Howenstine and Claude Prestidge and Frederick Royce and Julie Rice and Seilheimer, {Dan K.} and Joel Steelman and Ross Shepherds",
year = "2006",
month = "12",
doi = "10.1210/jc.2006-1101",
language = "English",
volume = "91",
pages = "4925--4929",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis

T2 - Results of a multicenter randomized controlled trial

AU - Hardin, Dana S.

AU - Adams-Huet, Beverley

AU - Brown, Daniel

AU - Chatfield, Barbara

AU - Dyson, Maynard

AU - Ferkol, Thomas

AU - Howenstine, Michelle

AU - Prestidge, Claude

AU - Royce, Frederick

AU - Rice, Julie

AU - Seilheimer, Dan K.

AU - Steelman, Joel

AU - Shepherds, Ross

PY - 2006/12

Y1 - 2006/12

N2 - Context: This multicenter, randomized, controlled, crossover trial of prepubertal children with cystic fibrosis (CF) tests the hypotheses that recombinant human GH (rhGH) treatment 1) improves height, weight, lean mass, and bone content irrespective of baseline measures; 2) improves clinical status and quality of life; and 3) has continued effect after cessation after 1 yr of treatment. Methods: Sixty-one prepubertal subjects (≤25th percentile for height and weight) were randomized into two groups: daily rhGH treatment or no treatment groups for 1 yr. In yr 2, treatments were crossed over. Outcome measures included serial standardized height and weight, number of hospitalizations and antibiotic courses, random blood glucose levels, lean mass, bone mineral content, pulmonary function, nutritional intake, and CF quality of life questionnaires. Results: Groups were similar at baseline and prepubertal during the entire study. After 1 yr, GH showed significantly greater gain in height, weight, lean mass, and bone mineral content. Gain in height was similar regardless of baseline. There were fewer hospitalizations in the rhGH-treated group and improvement in CF quality of life questionnaires measures of weight and body image. There was no difference in pulmonary function between groups. Results were similar in those treated with rhGH the second year. After cessation of rhGH treatment, there was sustained effect for increased height and weight velocity, as well as accrual of bone mineral. Conclusion: rhGH therapy improves height and weight, decreases the number of hospitalizations, and improves quality of life in prepubertal children with CF. These effects are sustained after rhGH is discontinued.

AB - Context: This multicenter, randomized, controlled, crossover trial of prepubertal children with cystic fibrosis (CF) tests the hypotheses that recombinant human GH (rhGH) treatment 1) improves height, weight, lean mass, and bone content irrespective of baseline measures; 2) improves clinical status and quality of life; and 3) has continued effect after cessation after 1 yr of treatment. Methods: Sixty-one prepubertal subjects (≤25th percentile for height and weight) were randomized into two groups: daily rhGH treatment or no treatment groups for 1 yr. In yr 2, treatments were crossed over. Outcome measures included serial standardized height and weight, number of hospitalizations and antibiotic courses, random blood glucose levels, lean mass, bone mineral content, pulmonary function, nutritional intake, and CF quality of life questionnaires. Results: Groups were similar at baseline and prepubertal during the entire study. After 1 yr, GH showed significantly greater gain in height, weight, lean mass, and bone mineral content. Gain in height was similar regardless of baseline. There were fewer hospitalizations in the rhGH-treated group and improvement in CF quality of life questionnaires measures of weight and body image. There was no difference in pulmonary function between groups. Results were similar in those treated with rhGH the second year. After cessation of rhGH treatment, there was sustained effect for increased height and weight velocity, as well as accrual of bone mineral. Conclusion: rhGH therapy improves height and weight, decreases the number of hospitalizations, and improves quality of life in prepubertal children with CF. These effects are sustained after rhGH is discontinued.

UR - http://www.scopus.com/inward/record.url?scp=33845479895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845479895&partnerID=8YFLogxK

U2 - 10.1210/jc.2006-1101

DO - 10.1210/jc.2006-1101

M3 - Article

VL - 91

SP - 4925

EP - 4929

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 12

ER -